Navigation Links
Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Date:9/28/2011

BASKING RIDGE, N.J., Sept. 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Sofinnova Japan Biopharma Partnering Conference at 2:50 p.m. JST on October 4, 2011 in Tokyo, Japan.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.

The Sofinnova Japan Biopharma Partnering Conference connects premier biotechnology companies from North America and Europe with Japanese licensing and business development executives.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two agents both adminis
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
4. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
5. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
6. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
9. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
10. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
11. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, one ... , has launched FluFree.com, a website designed to ... For 20 years, Passport Health has provided ... flu. The launch of FluFree.com is designed to address ... the number of people who actually chose to get ...
(Date:9/30/2014)... September 2014 ... Acutus Medical, Inc. ... 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit zur ... komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen bzw. ... zusätzlichen Finanzierung über 26,2 Mio. USD ...
(Date:9/30/2014)... , Sept. 30, 2014  Arena Solutions, the ... today announced its Fall 2014 release, which includes ... and Arena DataExtract – and significant ... available products are focused specifically on speeding time ... aggregation of a complete history of tribal knowledge ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
(Date:9/30/2014)... West Palm Beach, Florida (PRWEB) September 30, 2014 ... of Florida make the treatment of gum disease ... traditional treatments of the past. , “If you’ve ever felt ... into ice cream or sip a cold beverage, it’s possible ... Herbert Salisbury , who is a general dentist in ...
(Date:9/30/2014)... (HealthDay News) -- Medicare should cover low-dose computed tomography ... the disease, a coalition of more than 60 patient ... the Lung Cancer Alliance, the Society of Thoracic Surgeons, ... and the American Society of Clinical Oncology, made its ... Centers for Medicare & Medicaid Services (CMS). Such ...
(Date:9/30/2014)... made progress in reducing the stigma associated with seeking ... stress disorder, but more improvement is still needed, according ... of both the Defense Department and the Veterans Health ... still do not seek needed care for mental ... to promote treatment as a way to reduce stigma, ...
(Date:9/30/2014)... a gene mutation that causes a rare premature aging ... block the rapid, unstoppable cell division that makes cancer ... Michigan and the U-M Health System recently discovered a ... in which precious hematopoietic stem cells can,t regenerate and ... are prone to cancer and bone marrow failure. ...
(Date:9/30/2014)... FDA-approved injectable dermal fillers (i.e. hyaluronic ... in several procedures that are performed to restore ... primarily used for wrinkle treatment of the skin, ... are being used as popular treatments in nonsurgical ... the hands. (1) (2) Dr. Cynthia Elliott of ...
Breaking Medicine News(10 mins):Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4
... Hopkins Kimmel Cancer Center researchers say preliminary studies show ... able to reduce or eliminate the last remaining cancer ... the drug Imatinib mesylate (Gleevec). Gleevec, one of ... CML patients, destroys most leukemic cells in the body, ...
... new study, scientists have searched for mutations in the gene regions ... samples from a single tumour type to be sequenced to date. ... type of kidney cancer, with 102,000 deaths worldwide each year. It ... its nature is remarkably consistent and the majority of cases ...
... arthritis (RA) patients are partially protected by the influenza ... determined that while the flu vaccine is safe, it ... months following rituximab treatment. Previous influenza vaccination in ... some defense to influenza strains. RA activity was ...
... /CNW/ - A recent evaluation by the Centre for Addiction ... alcohol use can be effective in changing drinking behaviours and ... first evaluation of its kind, the study published in ... online screener www.CheckYourDrinking.net, reduced their alcohol consumption by 30% - ...
... of mental health professionals, emergency response experts, and researchers ... results of a study that shows serious emotional disturbances ... Category 3 storm ravaged the Gulf Coast in August ... of the Journal of the American Academy of ...
... the US population becomes increasingly obese while smoking rates continue ... contributor to the burden of disease and shortening of healthy ... the February 2010 issue of the American Journal of ... College of New York calculate that the Quality-Adjusted Life Years ...
Cached Medicine News:Health News:Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind 2Health News:Unraveling kidney cancer 2Health News:Unraveling kidney cancer 3Health News:Efficacy of flu vaccine drastically reduced for RA patients treated with rituximab 2Health News:Technology new gateway into treatment for problem alcohol users: Study 2Health News:Obesity now poses as great a threat to quality of life as smoking 2
... oxygen flowmeters., ,Options: , ... S to model number. Example: ... add suffix C to model ... Double Flowmeters with Power Take-Off, ...
... flowmeters., ,Options: , For ... to model number. Example: FMC107S. ... suffix C to model number. ... Flowmeters with Power Take-Off, add ...
... Slim Line Flowmeters with brass and ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... Flowmeters with brass and aluminum body., ... add suffix S to model number. ... add suffix C to model number. ... with Power Take-Off, add PT to ...
Medicine Products: